Sirona Biochem to hold May 22 AGM in Vancouver
SIRONA BIOCHEM ANNOUNCES CHANGE OF LOCATION OF ANNUAL GENERAL MEETING
The board of directors of Sirona Biochem Corp. has considered current COVID-19 public health restrictions and has determined it to be in the best interests of the company and its shareholders to hold the company's annual general meeting (AGM) at the offices of Sirona Biochem, suite 1600, room 16D 595, Burrard St., Vancouver, B.C., V7X 1L4.
The AGM will be held on Friday, May 22, 2020, at 9 a.m. PT. All other matters of the AGM remain the same as published in the AGM proxy materials mailed to shareholders and posted on SEDAR.
We seek Safe Harbor
- Published in News Home, Sirona Biochem
Sirona Biochem: Interview with Chief Scientific Officer Dr. Deliencourt-Godefroy on the Development Pipeline
Canada NewsWire
VANCOUVER, April 14, 2020
VANCOUVER, April 14, 2020 /CNW/ – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona“) is pleased to inform its shareholders that a video interview with its Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy, has been published by Austrian journalist Joachim Brunner (www.smallcapinvestor.de).
Here is a short sneak preview in the following Q&A format:
Q. What makes your (technology) platform so unique?
Q: What is your (development) focus now?
A. So, we have the anti-wrinkle (compound). It is working well. We have made some good advance…
Q: What is the next big thing for you?
The interview can be viewed at www.youtu.be/vDLtSUR2OC8 or on Sirona’s website www.sironabiochem.com.
On another note, Sirona will be attending the 2020 BIO International Convention, June 8-12, 2020. The conference will be held virtually and will allow Sirona to present its technology to key pharmaceutical companies. Virtual BIO One-on-One Partnering meetings will also take place. Sirona is adapting to industry changes driven by the evolving impact of COVID-19. These changes have been seamless for the team and in many cases have improved the ability to operate globally.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona’s subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments.
For more information, please visitwww.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
______________________________
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2020/14/c2071.html
Contact:
For more information regarding this press release, please contact: Investor Enquiries: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com; Corporate Enquiries: Dr. Howard Verrico, CEO, Chairman of the Board, Sirona Biochem Corp., Phone: 1.604.641.4466, Email: info@sironabiochem.com
© 2020 Canjex Publishing Ltd. All rights reserved.
- Published in Bio technology, News Home, Sirona Biochem
SIRONA BIOCHEM INITIATES COVID-19 AND INFECTIOUS DISEASES DEVELOPMENT PROGRAM
Sirona Biochem Corp.’s French subsidiary lab, TFChem, has initiated an anti-viral program to produce potential new anti-viral agents to assist in combating COVID-19 and other infectious diseases.
After two months of extensive research, TFChem scientists have determined the proprietary platform technology can be applied to develop new antiviral compounds. Work on this program has begun with a goal to produce new therapies in three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. These categories are all Glycosides with a carbohydrate core and therefore suitable for application of the technology. The goal is to develop novel multi-target antiviral compounds, affecting different steps of the viral life cycle. The company believes there is a high therapeutic potential for these Glycosides.
Viruses are a leading cause of death globally. Therapies to treat most viral infections are limited and the emergence of new viruses can greatly endanger society, as is currently the case with the pandemic caused by COVID-19, also known as Coronavirus or SARS-CoV-2. There is a need to identify novel, effective and safe drugs to treat viral infections. Awareness of the value of this project and other antiviral projects ongoing globally has become apparent.
“We have the financial resources to initiate this project and anticipate we will secure further non-dilutive financing to support the project ongoing. We are working to secure new senior laboratory technicians to join our current team at TFChem and have identified suitable candidates within France that will greatly expand our capabilities. We will also reach out to our current partners to explore how their capabilities can assist us in this project. None of these efforts will affect our current core projects which are principally managed by different team members than are involved in early stage compound synthesis,” said Dr. Howard Verrico, CEO of Sirona Biochem.
“These are difficult times with our global battle against COVID-19. We are receiving tremendous support from the French government and have a dedicated team who are always searching for new opportunities to apply our technology. Dr. Geraldine Deliencourt-Godefroy, our Chief Scientific Officer, has a proven ability to identify projects with significant probabilities of clinical success. On her recommendation and the recognition to potentially deliver novel therapies that can benefit the global population, we have decided to proceed with this program,” Dr. Verrico added.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona’s subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
We seek Safe Harbor.
- Published in Bio technology, News Home, Sirona Biochem
Sirona Biochem: Letter to the Shareholders
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF)(“Sirona”) is pleased to provide the following update:
To our valued Shareholders,
Over the last several weeks, Sirona Biochem’s management has been monitoring the recent increase in cases of Coronavirus (COVID-19), as we are sure many of you have. As an international organization, operating on three continents, Sirona has been one of the many companies affected by recent events. I want to assure you that we’re taking all necessary steps to advance our projects while minimizing delays and remaining a responsible corporate citizen. While all projects are moving forward, there have been some unavoidable delays and necessary rescheduling.
The health and safety of our employees and consultants is our paramount concern. During these uncertain times, this simple fact has been at the heart of all our discussions. To that end, we have taken numerous proactive measures to address the situation at hand, including:
- We have implemented a work from home policy for our employees and consultants (outside of our lab) to ensure we minimize the opportunity for spreading the virus. Historically we have operated virtually for much of our work and this transition has required minimal effort and has resulted in no loss of productivity.
- We have delayed travel. Fortunately, our strong established relationships with our current partners has allowed this step to limit the impact on moving our projects forward. We will restore travel as soon as it is deemed appropriate, including travel to China.
- We have not been required to suspend operations at the lab as part of a 15-day country wide lockdown in France. We will continue to cooperate with all government measures in the country’s in which we operate.
We will not achieve all our goals for this quarter as originally planned, but we still anticipate meeting all goals near term. Sirona has completed preparation for the increased dose (0.4%) clinical study for its skin lightening compound TFC-1067. Starting this clinical trial is the objective most delayed since obtaining formulation supplies from China were delayed pushing the potential trial into summer months. We are currently communicating with a global company (that plans to participate in this trial) to determine an ideal start date. Their participation in the trial is a tremendous added value to Sirona.
Other exciting news is anticipated regarding TFC-039 as stated in our last update. Extensive progress has been made and an announcement is anticipated. We are fortunate to have ample working capital to achieve our goals and are in no need to contemplate any dilutive capital raise. In fact, we are considering an expansion in the lab team to bring added resources to accelerate an exciting new project. Further details of this project and other projects will be forthcoming as we integrate our partners into a unified plan.
At Sirona Biochem, we pride ourselves on delivering exciting new therapeutics and cosmetic ingredients to partners using our proprietary platform technology. We will continue to monitor the COVID-19 situation and follow the directives and advice of the World Health Organization (WHO) and the governmental authorities for as long as necessary. As a shareholder I share your frustrations with current overall market conditions. By demonstrating our ability to navigate these challenging times and grow the company we hope to give shareholders the confidence needed to regain the value of their investment.
Dr. Howard Verrico, CEO
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona’s subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments.
For more information, please visit www.sironabiochem.com.
- Published in Life Sciences, News Home, Sirona Biochem
Strategic Collaboration Planned to Bring Sirona’s Product Pipeline to Commercial-Ready Stage
VANCOUVER, March 4, 2020 /CNW/ – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona“) is pleased to announce that it has signed a Letter of Intent (“LOI”) with the Chinese pharmaceutical company, Beijing Huaxi Pharma Co, Ltd. (“Huaxipharm“), ranked number five in the field of pharmaceutical development in China, to engage in a collaborative effort to bring Sirona’s product pipeline to commercial-ready stage for the global market.
Huaxipharm will co-develop on all steps to complete full commercialization of the products created by Sirona. This includes preclinical, clinical development, regulatory, commercial scale up and manufacturing for commercial applications of Sirona’s compounds for indications mutually agreed upon in the definitive agreement. Huaxipharm will receive a determined percentage ownership of the commercialized product for global sales as results of its inputs in the process of product commercialization.
The LOI is representative of the commitment of both organizations to work together. Sirona and Huaxipharm can now move to complete negotiations of a definitive agreement which should be completed in Q2/2020. Once Huaxipharm is publicly listed, Sirona management anticipates the relationship going well beyond the service and development agreement.
“Huaxipharm is a partner that can provide a new level of product development both in China and globally. Their expertise in active ingredients as well as a solid understanding of the CDFA navigation will benefit Sirona greatly with expansion into this marketplace. Huaxipharm has added expertise that will allow Sirona’s scientists to better develop new opportunities beyond drug discovery to fully commercially ready products,” said Dr. Howard Verrico, CEO of Sirona Biochem. “We are also monitoring the situation in China as it combats the Coronavirus. We have an established team in China which is continuing to move our projects forward. To date all projects are progressing. We have modified travel plans of our team but continue to conduct business virtually and will move meeting locations as necessary. We are also advancing on other fronts outside of China where we are optimistic to provide an update in the near term”, he added.
“After screening the worldwide market for promising collaboration partners for quite some time, we were pleased to get introduced to Sirona Biochem and quickly realized the enormous potential of their platform technology. We are looking forward to finalizing our due diligence and definitive agreement as soon as possible so that we can get to work in bringing new and innovative Sirona compounds to the market,” said Dr. Hua Bi, CEO of Beijing Huaxi Pharma.
About Beijing Huaxi Pharma
Beijing Huaxi Pharma (“Huaxipharm”) is a leading company in the field of pharmaceutical development, founded in 2003. For the 16 years since establishment, Huaxipharm has had many achievements, including creating a high-quality proficient team in pharmaceutical technology development and management, building up a core capability in pharmaceutical chemistry manufacturing and controls (CMC) and establishing new drug development that is compliant with international market standards with respect to: R&D environment, lab equipment, human resource allocation, quality system and management system.
Huaxipharm has recently realized its successful transformation from a technology enterprise to a pharmaceutical development and manufacturing company through M&A and reorganization. Its current business covers independent development and manufacturing of API, oral solid formulation for global markets with the international GMP certification. It also undertakes contract manufacturing or OEM business such as for nasal spray, eye drops and other liquid preparations by international technology transfer that are compliant to international GMP certification.
In 2015, Huaxipharm was listed as one of the top-five companies in China for the number of pharmaceuticals receiving IND approvals from China’s CFDA (after Hengrui, Bayer, Yangzi River and Pfizer). The Company has made significant achievements in promoting the Chinese pharmaceutical industry, completing tens of tech transfers to the top pharmaceutical companies in China in API synthesis optimization and pharmaceutical formulation for large-scale production.
Huaxipharm is seeking cooperation or partnership with outstanding enterprises for providing global market with high-quality pharmaceuticals of social benefits, aspiring to become a respected international pharmaceutical company.
Huaxipharm has intention to pursue an IPO at the Hong Kong Stock Exchange.
For more information, visit: www.huaxipharm.com
(Note: the web site is currently being updated as a priority task in response to the planned collaboration)
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona’s subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments.
For more information, please visit www.sironabiochem.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content: http://www.newswire.ca/en/releases/archive/March2020/04/c2022.html
Contact:
regarding this press release, please contact: Investor Enquiries: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com; Corporate Enquiries: Dr. Howard Verrico, CEO, Chairman of the Board, Sirona Biochem Corp., Phone: 1.604.641.4466, Email: info@sironabiochem.com
© 2020 Canjex Publishing Ltd. All rights reserved.
- Published in News Home, Sirona Biochem
Sirona Biochem Announces Change of Auditor
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC:SRBCF) (the “Company”) announces that it has changed its auditors from MNP LLP (the “Former Auditor”) to DeVisser Gray LLP (the “Successor Auditor”) effective January 27, 2020 and the board of directors of the Company appointed the Successor Auditor as the Company’s auditor effective January 27, 2020 until the next Annual General Meeting of the Company. There were no reservations in the Former Auditor’s audit reports for the relevant period, being the financial years ended October 31, 2018 and October 31, 2017 and any period subsequent to the most recently completed financial year for which an audit report was issued and preceding the resignation of the Former Auditor. In accordance with National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”), the Company has filed a Change of Auditor Notice (the “Notice”) on SEDAR together with letters from both the Former Auditor and Successor Auditor, with each lettering confirming agreement with the statements contained in the Notice, as applicable. There were no reportable events as defined in NI 51-102 between the Former Auditor and the Company.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona’s subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments.
For more information, please visit www.sironabiochem.com
- Published in Sirona Biochem
Sirona Biochem: 100% Safety in Final Tox Study for Increased Concentration of TFC-1067
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona“) announces that the final toxicology test, a Human Repeated Insult Patch Test (“HRIPT”), has successfully been completed. Sirona is now in preparation for the increased dose (0.4%) clinical study for its skin lightening compound TFC-1067.
The HRIPT study was coordinated by Eurofins Dermscan in Poland (www.eurofins.com) and was executed by Eurofins EVIC Product Testing Romania under the direction of a clinical dermatologist. During the study, the formulation containing 0.4% TFC-1067 was applied to 103 participants repeatedly, 9 times, to the same site over a period of three consecutive weeks to induce a possible allergy. After a minimal 2-week rest period, another single application of the product was applied, under patch, to the induction site and to a new site for a defined time in order to reveal a possible induced allergy.
The cream containing 0.4% TFC-1067 showed 100% safety in all subjects. No negative reactions were observed during the study period.
The written report of the study concluded the following: “Based on these results, the product has a very good skin compatibility and does not show a sensitizing effect.”
“Again, we’ve received excellent results with our skin lightening compound TFC-1067. This compound is very safe at our current dose and anticipated to be more effective for creating a brighter, more even skin tone,” said Dr. Howard Verrico, CEO of Sirona Biochem. “We are now working with Eurofins Dermscan to establish the protocol for the clinical study which we expect to start within the next few months.”
The clinical trial is anticipated to be a value-add for the compound. Current licenses and ongoing product development by partners for TFC-1067 will not be delayed by the studies.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona’s subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments.
For more information, please visitwww.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2020/22/c1715.html
Contact:
regarding this press release, please contact: Investor Enquiries: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com; Corporate Enquiries: Dr. Howard Verrico, CEO, Chairman of the Board, Sirona Biochem Corp., Phone: 1.604.641.4466, Email: info@sironabiochem.com
- Published in News Home, Sirona Biochem
SIRONA BIOCHEM ANNOUNCES GRANT OF STOCK OPTIONS
Sirona Biochem Corp. has granted an aggregate of 6.8 million incentive stock options to management, independent directors and consultants of the company. The options to purchase common shares in the capital of the company at a price of 45 cents per common share will be for periods ranging from one to 10 years. The options have been granted under the terms of the company’s stock option plan.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
We seek Safe Harbor.
- Published in News Home, Sirona Biochem
Sirona Biochem Reports 100% Safety in First Tox Study for Increased Concentration of TFC-1067
Momentum Public Relations
Press Release: December 2, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona“) announces that the first toxicology test, in preparation for the new clinical study, has been completed with positive results.
In anticipation of a clinical study in Q2 of 2020, Sirona has completed the first required toxicity study for the increased dose (0.4%) of TFC-1067. The new formulation has been tested with a “cutaneous compatibility assessment” at Cosmepar in France (https://www.cosmepar.fr/en/), which is a patch on 12 subjects for a period of 48 hrs. The test is used to determine whether the formulation is an irritant to skin. TFC-1067 .4% was found to be a non-irritant in 100% of subjects in the patch test.
In a similar study1 (published in the Annals of Dermatology 2017), 20 volunteers were patch-tested with varying levels of hydroquinone (HQ) alone and in combination with retinoic acid (RA). This combination is used in some skin lighteners to enhance the efficacy. Results of the study showed that HQ alone at 2% was an irritant in 30% of participants and up to 70% of participants at 4%. 4% is a dose often used in prescription level formulations, such as Tri-Luma2, for melasma. In the same study, HQ combined with retinoic acid was an irritant in as many as 75% of subjects with some developing edema (inflammatory swelling of the skin). Post inflammatory responses to HQ can result in permanent discoloration to the skin.
Sirona is currently carrying out a second required tox study for TFC-1067. This study is a human repeat insult patch test (HRIPT). The HRIPT study will be 3 consecutive weeks with volunteers having repeat doses administered on a patch. Results of this study will be available early Q1 2020. Following the HRIPT, a toxicologist will examine the results for approval of the next clinical efficacy trial. Arrangements are now being made in preparation for the planned clinical trial to follow directly after the approval. We remain on target for this expedited process.
“The data we’ve received is consistent with claims that TFC-1067 is very safe at therapeutic dose. At .2% TFC-1067 was equal to HQ 2% for lightening and better than 2% hydroquinone for creating an even skin tone and we anticipate that our new dose will be more effective and quicker acting,” said Dr. Howard Verrico, CEO of Sirona Biochem. “We will not compromise on the safety of TFC-1067 as we continue to explore its full potential both in benefit to the consumer and commercial opportunity to our Sirona shareholders. It cannot be stressed enough that there is a significant unmet need for a safe alternative for people wishing to manage dark spots and create more uniform skin. There are many potentially toxic formulations available on the market that will ultimately damage the skin. Sirona Biochem will continue to strive for products that people can trust.”
The planned clinical trial is anticipated to be a value-add for the compound. Current licenses and ongoing product development by partners for TFC-1067 will not be delayed by the studies.
_________________________________ |
|
1 |
Increased Skin Irritation by Hydroquinone and Retinoic Acid Used in Combination https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705352/ |
2 |
Tri-Luma https://www.triluma.com/ |
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona’s subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments.
For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2019/02/c2463.html
Contact:
Investor Enquiries: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com; Corporate Enquiries: Dr. Howard Verrico, CEO, Chairman of the Board, Sirona Biochem Corp., Phone: 1.604.641.4466
- Published in Life Sciences, News Home, Sirona Biochem
Sirona Biochem Proceeds to First Clinical Tests for Higher Concentrations to Increase Commercial Value of Skin Lightening Compound TFC-1067
Momentum Public Relations
Press Release: October 30, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona“) is pleased to announce that testing of the higher concentration formulation of TFC-1067, first announced in June 2019, will proceed to Human Patch Test, followed by a Human Repeat Insult Patch Test (HRIPT).
Sirona’s scientific team at TFChem and the Senior Toxicologist at CEHTRA (www.cehtra.com) have reviewed recent in-vitro safety assays and verified that the compound can be tested at double the prior concentration. This concentration was chosen as we aim to achieve maximum efficacy while maintaining TFC-1067’s excellent safety profile.
The Human Patch Test for cutaneous irritation will be conducted under physician supervision at Cosmepar (www.cosmepar.fr/en/) in France. Cosmepar’s specialized services include evaluating the tolerance of cosmetic products. The results from this test are expected within 4 weeks.
In addition, a Human Repeat Insult Patch Test (“HRIPT”) will be conducted to determine any potential irritation or sensitization issues. The HRIPT will be performed on one hundred volunteers selected by Dermscan (www.dermscan.com/en/). Results are expected in January 2020.
The higher concentration is being used in Sirona’s next generation formulation developed specifically to maximize the efficacy of TFC-1067. The formulation was developed by cosmetic expert, Gael Boutry of Global Beauty Consulting in France (www.globalbeautyconsulting.com/).
“We are excited to make this progress towards a second clinical trial of TFC-1067. The in-vitro testing has allowed us to safely double the concentration, but the in-vitro tests have their own limitations so anything over double has been deferred at this time. Safety is our priority and we will proceed to develop TFC-1067 in a stepwise approach. The new formulation is also anticipated to make a significant improvement in efficacy of TFC-1067,” said Dr. Howard Verrico, CEO of Sirona Biochem.
“A full clinical trial to assess efficacy is anticipated to begin in Q1 2020. A further update will be made prior to this trial. All testing will be done with cash on hand and will not delay any ongoing partnering discussions. TFC-1067 0.2% has already proven superior to hydroquinone 2% in creating a uniform skin tone and we anticipate even more exciting results with the new higher concentration formulation. The value of this benefit to the consumer and ultimately for our shareholders cannot be underestimated and will improve the commercial value for our shareholders,” added Dr. Verrico.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
- Published in Life Sciences, News Home, Sirona Biochem